Vafidemstat

An overview of the drug Vafidemstat

Vafidemstat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Vafidemstat is a novel pharmaceutical drug under investigation for its potential therapeutic effects in various neuropsychiatric disorders. It is classified as a histone deacetylase inhibitor (HDAC inhibitor), which modulates the expression of genes by altering the acetylation status of histones.

Mechanism of Action

Vafidemstat functions primarily as an HDAC inhibitor. By inhibiting histone deacetylases, it increases the acetylation of histone proteins, leading to a more relaxed chromatin structure and increased gene expression. This mechanism is thought to underlie its potential therapeutic effects in neuropsychiatric disorders by modulating the expression of genes involved in neurotransmission, neuroplasticity, and inflammation.

Therapeutic Applications

Vafidemstat is being investigated for its use in treating a variety of neuropsychiatric conditions, including:

• Schizophrenia
• Bipolar disorder
• Major depressive disorder
• Autism spectrum disorder

The drug's ability to modulate gene expression may help alleviate symptoms associated with these disorders by restoring normal patterns of neuronal activity and connectivity.

Clinical Trials

Vafidemstat is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are designed to assess its impact on symptom severity, cognitive function, and overall quality of life in patients with neuropsychiatric disorders.

Side Effects

As with many HDAC inhibitors, potential side effects of Vafidemstat may include:

• Gastrointestinal disturbances
• Fatigue
• Headache
• Dizziness

Ongoing clinical trials aim to further elucidate the safety profile of Vafidemstat.

Research and Development

The development of Vafidemstat is part of a broader effort to create targeted therapies for complex neuropsychiatric conditions. By focusing on epigenetic modulation, researchers hope to provide more effective treatments with fewer side effects compared to traditional psychotropic medications.

Related Pages

• Histone deacetylase inhibitor
• Neuropsychiatric disorder
• Epigenetics

• 
  Vafidemstat